Evaluating Advances in the Treatment Landscape for Patients With Follicular Lymphoma

Matthew Matasar, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, discusses upcoming studies and encouraging advances that show promise in the continually evolving treatment landscape for patients with follicular lymphoma (FL). 

Dr Matasar discusses the anticipation of the future results of these studies, as well as the use of bispecific antibodies among patients with relapsed/refractory (R/R) follicular lymphoma.  

Transcript: 

Hi, I'm Dr. Matthew Matasar, the chief of blood disorders here at Rutgers Cancer Institute of New Jersey. The therapeutic landscape for patients with follicular lymphoma is definitely continuing to evolve at a breakneck pace. 

We have recent approval of mosunetuzumab monotherapy for patients with relapsed or refractory follicular lymphoma. I continue to be very optimistic about bispecific [antibodies] in general in this disease state, however, and we have a number of very exciting clinical trials that are open or being currently planned to explore the use of mosunetuzumab alone or in combination [with] earlier lines of therapy.

Work such as that being led by Adam Olszewski [Adam J. Olszewski, MD, Brown University, Providence, Rhode Island], in which we're participating, looking at mosun[etuzumab] monotherapy in patients with newly diagnosed follicular lymphoma, using it as monotherapy or intensifying it with combination lenalidomide for patients who don't achieve a rapid complete response. 

We're also seeing the number of combination approaches of mosunetuzumab plus X, Y, or Z for patients with relapsed or refractory follicular lymphoma, work that we're helping lead, including mosunetuzumab in combination with tafasitamab and lenalidomide, but certainly a number of other ongoing and promising combinations. You're looking at mosunetuzumab for patients with relapsed or refractory follicular lymphoma. 

I think that the ceiling is very high for bispecifics in this disease state, and I look forward to seeing how this field continues to evolve.

Source: 

Bartlett N, Sehn L, Matasar M, et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: updated results from a pivotal phase II study. Clinical Lymphoma Myeloma and Leukemia. Vol 23, 2023. doi:10.1016/S2152-2650(23)01361-7